H4RT Trial

The High-volume Haemodiafiltration vs High-flux Haemodialysis Registry Trial

Our research aims to establish the effectiveness of haemodialysis versus haemodiafiltration in the treatment of kidney disease.

End stage kidney disease affects around 55,000 people in the UK. Almost half of these people will have blood cleaning treatment known as haemodialysis at a hospital.

The addition of filtration (the removal and replacement of fluid) to regular haemodialysis is known as haemodiafiltration. This does not change the dialysis procedure as far as the patient is concerned - it is still 4 hours 3 times a week, it just requires change in equipment and nurse practice.

By removing toxins more effectively, haemodiafiltration may improve survival, infection rates and quality of life of patients.

Recruitment for the H4RT trial began in November 2017.

For further information about this research, please contact:

Dr Fergus Caskey - Trial Chief Investigator and Medical Director of UK Renal Registry

Dr Sunita Procter - Trial Manager

The study is funded by NIHR Health Technology Assessment.

Edit this page